News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
734,808 Results
Type
Article (41605)
Company Profile (266)
Press Release (692924)
Multimedia
Podcasts (97)
Webinars (20)
Section
Business (205124)
Career Advice (2036)
Deals (35661)
Drug Delivery (133)
Drug Development (81697)
Employer Resources (173)
FDA (16564)
Job Trends (15007)
News (347360)
Policy (32784)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2613)
Accelerated approval (55)
ADA (46)
Adcomms (29)
Allergies (190)
Alliances (49625)
ALS (225)
Alzheimer's disease (1830)
Antibody-drug conjugate (ADC) (513)
Approvals (17022)
Artificial intelligence (721)
ASCO (327)
Autoimmune disease (334)
Automation (63)
Bankruptcy (364)
Best Places to Work (11642)
BIO (64)
BIOSECURE Act (20)
Biosimilars (233)
Biotechnology (171)
Bladder cancer (203)
Brain cancer (74)
Breast cancer (794)
Cancer (6252)
Cardiovascular disease (502)
Career advice (1732)
Career pathing (44)
CAR-T (353)
CDC (58)
Celiac Disease (3)
Cell therapy (955)
Cervical cancer (54)
Clinical research (71541)
Collaboration (2187)
Commercialization (1)
Company closure (5)
Compensation (1488)
Complete response letters (84)
COVID-19 (2753)
CRISPR (115)
C-suite (1219)
Cystic fibrosis (156)
Data (8578)
Decentralized trials (3)
Denatured (29)
Depression (172)
Dermatology (97)
Diabetes (664)
Diagnostics (7021)
Digital health (63)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (356)
Drug pricing (202)
Drug shortages (31)
Duchenne muscular dystrophy (298)
Earnings (92293)
Editorial (67)
Employer branding (21)
Employer resources (153)
Events (120730)
Executive appointments (1119)
FDA (20529)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (35)
Funding (1838)
Gene editing (242)
Generative AI (61)
Gene therapy (749)
GLP-1 (1090)
Government (4751)
Grass and pollen (6)
Guidances (418)
Healthcare (19170)
Hematology (192)
HIV (89)
Huntington's disease (61)
IgA nephropathy (110)
Immunology and inflammation (299)
Immuno-oncology (101)
Indications (214)
Infectious disease (3119)
Inflammatory bowel disease (221)
Inflation Reduction Act (14)
Influenza (142)
Intellectual property (316)
Interviews (321)
IPO (16691)
IRA (50)
Job creations (3653)
Job search strategy (1432)
JPM (58)
Kidney cancer (20)
Labor market (111)
Layoffs (575)
Leadership (42)
Legal (7959)
Liver cancer (103)
Longevity (35)
Lung cancer (827)
Lymphoma (472)
Machine learning (65)
Management (60)
Manufacturing (1138)
Marketing (2)
MASH (208)
Medical affairs (1)
Medical device (14021)
Medtech (14188)
Mergers & acquisitions (20274)
Metabolic disorders (1639)
mRNA (226)
Multiple sclerosis (198)
NASH (17)
Neurodegenerative disease (455)
Neuropsychiatric disorders (109)
Neuroscience (3453)
Neurotech (1)
NextGen: Class of 2026 (6531)
Non-profit (4542)
Now hiring (81)
Obesity (752)
Opinion (294)
Ovarian cancer (237)
Pain (267)
Pancreatic cancer (348)
Parkinson's disease (389)
Partnered (35)
Patents (631)
Patient recruitment (747)
Peanut (66)
People (59929)
Pharmaceutical (60)
Pharmacy benefit managers (33)
Phase 1 (22313)
Phase 2 (31529)
Phase 3 (23446)
Pipeline (9713)
Policy (330)
Postmarket research (2572)
Preclinical (9475)
Press Release (64)
Prostate cancer (334)
Psychedelics (57)
Radiopharmaceuticals (342)
Rare diseases (1154)
Real estate (5977)
Recruiting (70)
Regulatory (25766)
Reports (56)
Research institute (2422)
Resumes & cover letters (354)
Rett syndrome (43)
RNA editing (24)
RSV (90)
Schizophrenia (182)
Series A (314)
Series B (230)
Service/supplier (11)
Sickle cell disease (119)
Special edition (24)
Spinal muscular atrophy (168)
Sponsored (48)
Startups (3651)
State (2)
Stomach cancer (18)
Supply chain (134)
Tariffs (87)
The Weekly (66)
Vaccines (1138)
Venture capital (120)
Weight loss (480)
Women's health (137)
Worklife (21)
Date
Today (104)
Last 7 days (479)
Last 30 days (2661)
Last 365 days (30348)
2026 (15801)
2025 (30198)
2024 (35242)
2023 (40113)
2022 (51227)
2021 (55756)
2020 (54135)
2019 (46578)
2018 (35067)
2017 (32157)
2016 (31527)
2015 (37609)
2014 (31354)
2013 (26388)
2012 (28593)
2011 (29289)
2010 (27360)
Location
Africa (744)
Alabama (93)
Alaska (7)
Arizona (366)
Arkansas (14)
Asia (39969)
Australia (6549)
California (13952)
Canada (3928)
China (1476)
Colorado (593)
Connecticut (609)
Delaware (432)
Europe (86575)
Florida (2099)
Georgia (445)
Hawaii (3)
Idaho (63)
Illinois (1139)
India (97)
Indiana (630)
Iowa (24)
Japan (591)
Kansas (133)
Kentucky (51)
Louisiana (58)
Maine (76)
Maryland (1653)
Massachusetts (9982)
Michigan (376)
Minnesota (754)
Mississippi (6)
Missouri (148)
Montana (33)
Nebraska (30)
Nevada (148)
New Hampshire (84)
New Jersey (3651)
New Mexico (30)
New York (3653)
North Carolina (1754)
North Dakota (9)
Northern California (7034)
Ohio (416)
Oklahoma (23)
Oregon (41)
Pennsylvania (2768)
Puerto Rico (31)
Rhode Island (52)
South America (1114)
South Carolina (88)
South Dakota (2)
Southern California (5532)
Tennessee (226)
Texas (2235)
United States (49150)
Utah (414)
Vermont (2)
Virginia (342)
Washington D.C. (81)
Washington State (1109)
West Virginia (4)
Wisconsin (132)
Wyoming (2)
734,808 Results for "amber ophthalmics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales
March 2, 2026
·
6 min read
Press Releases
Amber Therapeutics strengthens its Board and Leadership team, opens UK headquarters and expands EU feasibility study for mixed urinary incontinence, increasing momentum towards a pivotal trial in the US
February 24, 2026
·
5 min read
Press Releases
Institut du Cancer de Montpellier and TAE Life Sciences Launch AMBER Project to Bring BNCT to France
December 18, 2025
·
3 min read
Press Releases
Saptalis Pharmaceuticals Launches Cyclosporine Ophthalmic Emulsion 0.05% and Expands Product Portfolio
June 16, 2026
·
2 min read
Press Releases
Amneal Launches Bimatoprost Ophthalmic Solution, 0.01%
April 9, 2026
·
3 min read
Press Releases
UPSHER-SMITH LAUNCHES GENERIC VERSION OF RESTASIS® (CYCLOSPORINE OPHTHALMIC EMULSION 0.05%)
May 20, 2026
·
2 min read
Press Releases
ZEISS expands ophthalmic surgical workflows in Mexico with COFEPRIS approval for ARTEVO 850 and MICOR 700
May 13, 2026
·
5 min read
Drug Development
Amber Ophthalmics Announces First Patient Enrolled in NEXPEDE-1, a Phase 2/3 Clinical Trial Evaluating Nexagon for the Treatment of Persistent Corneal Epithelial Defects
Amber Ophthalmics, Inc. (Amber) , a privately held, clinical stage biopharmaceutical company, announced today that Dr. Mark S. Gorovoy from Gorovoy M.D. Eye Specialists has enrolled the first patient in the AMB-01-006 (NEXPEDE-1) study.
August 18, 2023
·
2 min read
FDA
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Amber Therapeutics, a UK-based medical technology company developing a breakthrough adaptive neuromodulation therapy to treat mixed urinary incontinence, announces the successful closing of its Series A financing raising a total of $100 million from leading healthcare and technology investors in the US and UK.
June 10, 2024
·
5 min read
Press Releases
Hexiris Ophthalmics Marks Scientific Milestones, Launches Digital Presence, and Announces Hands-On Dry Lab at COS Annual Meeting, Montreal
June 8, 2026
·
5 min read
1 of 73,481
Next
